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Abstract
Background: Laboratory professionals should indepen-
dently verify the correct implementation of metrological 
traceability of commercial measuring systems and deter-
mine if their performance is fit for purpose. We evaluated 
the trueness, uncertainty of measurements, and transfer-
ability of six clinically important enzyme measurements 
(alanine aminotransferase [ALT], alkaline phosphatase 
[ALP], aspartate aminotransferase [AST], creatine kinase 
[CK], γ-glutamyltransferase [γGT], and lactate dehydrogenase 
[LDH]) performed on the Abbott Alinity c analytical system.
Methods: Target values and associated uncertainties 
were assigned to three pools for each enzyme by using 
the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) reference measurement pro-
cedures (RMPs) and the pools were then measured on the 
Alinity system. Bias estimation and regression studies 
were performed, and the uncertainty associated with 
Alinity measurements was also estimated, using analyti-
cal performance specifications (APS) derived from biologi-
cal variability of measurands as goals. Finally, to validate 
the transferability of the obtained results, a comparison 
study between two Alinity systems located in Milan, Italy, 
and Bydgoszcz, Poland, was carried out.
Results: Correct implementation of traceability to the 
IFCC RMPs and acceptable measurement uncertainty ful-
filling desirable (ALP, AST, LDH) or optimal APS (ALT, CK, 
γGT) was verified for all evaluated enzymes. An optimal 
alignment between the two Alinity systems located in 
Milan and Bydgoszcz was also found for all enzyme 
measurements.
Conclusions: We confirmed that measurements of ALT, 
ALP, AST, CK, γGT, and LDH performed on the Alinity c 
analytical system are correctly standardized to the IFCC 
reference measurement systems and the system  alignment 
is consistent between different platforms.
Keywords: enzymes; standardization; traceability; 
 trueness; uncertainty.
Introduction
Serum enzymes are important biomarkers for the diag-
nosis and management of many organ-related diseases 
and are among the most requested tests in medical 
laboratories [1]. Standardization in clinical enzymology 
is therefore essential in order to provide global equiva-
lence of results in clinical samples, independently of the 
employed measuring system (MS) [2, 3]. To pursue this 
objective, the ‘reference system’ approach, based on the 
concepts of metrological traceability and a hierarchy of 
measurement procedures, should be applied [4]. In the 
standardization of enzyme measurements, a reference 
measurement procedure (RMP), which defines condi-
tions under which a given enzyme catalytic activity is 
measured, occupies the highest level of the traceabil-
ity chain [5, 6]. The International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) has estab-
lished RMPs for the most clinically important enzymes, 
which are now listed in the database of the Joint Com-
mittee on Traceability in Laboratory Medicine [7]. To 
fulfil the European Union 1998/79 Directive and the 
new 2017/746 Regulation on in vitro diagnostics (IVD) 
medical devices, manufacturers should align their com-
mercial MS to these RMPs [8]. This will permit to obtain 
equivalent results in clinical samples, independently of 
the employed MS and the individual laboratory where 
measurements are carried out. The achievement of inter-
laboratory agreement of enzyme activity measurements 
allows the use of common reference intervals, thus 
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facilitating result interpretation and ultimately improv-
ing patient care [3, 6, 9–14].
Despite the aforementioned approach being now clear 
in terms of role, responsibilities, and goals to be achieved, 
the enzyme measurement standardization seems often 
incorrectly implemented. This is largely resultant from 
some manufacturers continuing to market assays with 
different analytical selectivity for the same enzyme and, 
consequently, with demonstrated insufficient quality for 
the fulfilment of requirements for standardization [6, 15]. 
A sizeable bias toward the RMP measured values is some-
times observed in clinical results, suggesting the need for 
improvement of traceability implementation to higher-
order references [15, 16].
In addition to the manufacturers’ responsibility, 
laboratory professionals should independently verify the 
correct implementation of traceability to higher-order 
references and determine if the performance of the evalu-
ated MSs is fit for purpose [17, 18]. In doing this work, the 
definition of analytical performance specifications (APS) 
becomes essential to check if the evaluated determina-
tion is clinically usable and to ensure that the measure-
ment error does not prevail on the result. In 2014, the 1st 
European Federation of Clinical Chemistry and Labora-
tory Medicine (EFLM) Strategic Conference redefined the 
approaches for establishing APS [19, 20]. Among proposed 
models, the one based on the biological variability has 
been used to derive APS for enzymes [6, 21].
The aim of our study was to validate the trueness 
and to estimate the uncertainty of measurements of six 
clinically important enzyme measurements (alanine 
aminotransferase [ALT], alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], creatine kinase [CK], 
γ-glutamyltransferase [γGT], and lactate dehydrogenase 
[LDH]) performed on the Alinity c analytical system 
(Abbott Diagnostics), using APS derived from biological 
variability of measurands as goals. The transferability of 
the obtained results in two different European laborato-
ries was also evaluated.
Materials and methods
Preparation and value assignment of serum pools
For each of the six enzymes, three fresh-frozen human serum pools 
with different catalytic concentrations were prepared using leftover 
samples, following recommendations from the Clinical Laboratory 
and Standards Institute (CLSI) C37-A guideline and its recently released 
update [22, 23]. Catalytic concentrations of pools were distributed 
across the reportable range for each enzyme measurement, i.e. with 
concentrations around the upper reference limit, slightly elevated, and 
markedly abnormal. Each pool was then divided into 1-mL aliquots 
and stored in polypropylene cryovials at −80 °C until use.
Enzyme target values (and corresponding uncertainties) were 
assigned to each pool in the CIRME reference laboratory (Univer-
sity of Milan), by using the corresponding IFCC RMP [24–29]. In 
particular, the concentration of catalytic activity of each pool was 
measured in triplicate for 3 consecutive days and the target value 
for each enzyme was calculated as an average of the averages of the 
daily results. The uncertainty of the assigned value was calculated 
as a combined standard uncertainty, expanded with a coverage fac-
tor of 2 (95.45% level of confidence), taking into account the relative 
standard uncertainty of the repeated measurements for each enzyme 
(CV of the averages of the daily results divided by the square root of 
the number of determinations) and other components of uncertainty 
of the RMP arising from systematic effects, previously estimated by 
the CIRME laboratory from specific information and investigations 
related to calibration procedures for spectrometry, gravimetry, volu-
metry, potentiometry, and thermometry [3, 30, 31].
Verification of Alinity traceability
The traceability toward the IFCC RMPs for the six evaluated enzymes 
was verified using an Alinity c platform installed in the core labora-
tory of the ‘Luigi Sacco’ academic hospital in Milan. Table 1 reports 
the characteristics of six enzyme assays evaluated in this study. The 
system alignment to the manufacturer’s specifications was checked 
by measuring, before and after each analytical run, the three-level 
control material offered by Abbott as part of their CE-marked MS 
(Multichem S Plus Technopath, ref. 08P88) and by verifying that 
results for all enzymes were well within the ±10% range from the 
control target value declared by the manufacturer. On the day of 
measurements, aliquots of each pool were gradually thawed and 
then measured in triplicate. Correlations between Alinity and RMP 
results were assessed using Passing-Bablok regression and the bias 
was estimated on each of the three pools for each enzyme by com-
paring the mean of Alinity triplicates with the target values assigned 
to pools by the IFCC RMP. The traceability of Alinity assays to the 
RMP was considered rightly implemented if the mean percentage 
bias on the three pools was less than the bias specifications, derived 
by using the classical Fraser’s approach [32] and the biological 
variation data retrieved from the EFLM database [33] (Table 2). As 
biological variability data for total ALP are not available in this 
 database, APS for ALP measurements were derived from previously 
published studies [34, 35].
Estimate of measurement uncertainty of Alinity MS
The uncertainty associated with the enzyme measurements carried 
out by the Alinity MS was estimated according to the ISO 20914:2019 
technical specification [36]. In particular, the relative standard uncer-
tainty (uresult) was estimated by combining the uncertainty due to 
random effects (uRw) to the standard uncertainty of bias (ubias), using 
the formula 2 2bias Rwu u .√ +  The uresult was then multiplied by a cover-
age factor of 2 to obtain the expanded uncertainty (U). Three com-
ponents contributed to ubias: (a) the average difference between the 
obtained mean for the pool with enzyme concentration closer to that 
of control material employed for estimating intermediate reproduc-
ibility (see below) and the corresponding RMP target value, (b) the 
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bias variability (expressed as relative SD of individual bias divided 
by the square root of the number of measurements), and (c) the rela-
tive standard uncertainty of the target value assigned to the pool 
by the RMP. The uRw was estimated as intermediate reproducibility 
from 5-month (July–November 2019) consecutive measurement data 
(n = 120) of a serum-based fresh-frozen control material (Liquichek 
Unassayed Chemistry Control Level 2, Bio-Rad), randomly analyzed 
daily during the ordinary laboratory activity in Milan. This material 
has the characteristics previously recommended for correctly deriving 
the uncertainty of MS due to random effects [37]. The obtained U val-
ues were finally compared with the respective APS reported in Table 2.
Transferability of the Alinity performance across 
 laboratories
To verify if the traceability of enzyme results provided by the Alinity c 
located in Milan was extendable to other laboratories using the same 
MS, a comparison study was carried out with another Alinity c located 
in the Department of Laboratory Medicine of the Collegium Medicum 
in Bydgoszcz. Similar to what described earlier, fresh-frozen human 
serum pools at three clinically relevant concentrations for each 
enzyme were prepared in Bydgoszcz, aliquoted, and frozen at −80 °C. 
One aliquot for each pool was then sent to Milan in dry ice. After 
delivery, simultaneously in Milan and Bydgoszcz, pools were gradu-
ally thawed and assayed on the same day in triplicate by using the 
Alinity MSs, with each system alignment checked as described earlier. 
On each of the three pools for each enzyme, we compared the mean 
of triplicates obtained in Bydgoszcz with the mean value obtained in 
Milan (used as reference because previously validated for traceabil-
ity). The difference between the two MSs was considered acceptable 
if the mean percentage bias on the three pools (Bydgoszcz vs. Milan) 
was less than 1/3 of desirable bias goals reported in Table 2 [38].
Because the study involved anonymized leftover samples, it did 
not require approval by an Ethics Committee.
Results
Table 3 displays the enzyme target values assigned to the 
pools by the CIRME reference laboratory, together with 
Table 1: Characteristics of Abbott Alinity c enzyme assays evaluated in the study.
Enzyme   Code no.   Method principle   Calibration principle   Declared traceability   Employed reagent lot
ALT   08P1820   Kinetic spectrophotometric (NADH 
with pyridoxal-5′-phosphate)
  Calibration factor 
(7658)
  IFCC RMP   75228UN18
ALP   08P2020   Kinetic spectrophotometric (para-
nitrophenyl phosphate)
  Calibration factor 
(2290)a
  IFCC RMP   86495UN18
AST   08P2320   Kinetic spectrophotometry (NADH 
with pyridoxal-5′-phosphate)
  Calibration factor 
(6835)
  IFCC RMP   61147UN18
CK   08P4220   Kinetic spectrophotometric (N-acetyl-
L-cysteine)
  Calibration factor 
(9081)
  Not declaredb   00675UN19
γGT   07P7320   Kinetic spectrophotometric (L-gamma-
glutamyl-3-carboxy-4-nitroanilide)
  Calibration factor 
(8372)a
  IFCC RMP   68895UN18
LDH   07P7420   Kinetic spectrophotometric (lactate to 
pyruvate)
  Calibration factor 
(11180)
  IFCC RMP   61976UN18
RMP, reference measurement procedure. aNote that for ALP and γGT Abbott Diagnostics offers two different calibration options, one declared 
traceable to the respective IFCC RMP and another derived from an optimized enzymatic reaction developed internally by the manufacturer. 
bNo information about traceability to higher-order references is reported by the manufacturer. However, according to the Abbott Diagnostics 
package insert (Alinity c. Creatine kinase reagent kit, G71241R03B8P420, revised February 2018), this method correlates well with the 
Architect CK measuring system (Alinity = 1.02 Architect–1 U/L; n = 124, activity range, 14–3844 U/L), which, in turn, is standardized to the 
IFCC RMP.
Table 2: Analytical performance specifications for bias and 







Desirable   Optimum Desirable   Optimum
ALT   ±7.7%   ±3.9%   ±10.1%   ±5.1%
ALP   ±5.5%   ±2.8%   ±6.0%   ±3.0%
AST   ±5.7%   ±2.8%   ±9.8%   ±4.9%
CK   ±8.8%   ±4.4%   ±15.4%   ±7.7%
γGT   ±10.5%   ±5.3%   ±8.6%   ±4.3%
LDH   ±3.4%   ±1.7%   ±5.2%   ±2.6%
All biological variability information (i.e. within-subject CV [CVI] 
and between-subject CV [CVG]) is derived from the EFLM database 
(https://biologicalvariation.eu), except for ALP derived from refs. 
[34] and [35]. aCalculated as +2 2 0.5I G0.250(CV CV )  (desirable) and 
+2 2 0.5I G0.125(CV CV )  (optimum). bCalculated as standard uncertainty 
as 0.50 CVI (desirable) and 0.25 CVI (optimum), and expanded by 
multiplying by a coverage factor of 2 (95.45% level of confidence). 
Note that for measurement uncertainty, the relevant goal that 
should be fulfilled is that related to the allowable random variability 
of patient results, as the correct trueness transfer along the 
metrological traceability chain should allow the achievement of 
unbiased (or negligibly biased) results.
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corresponding U. Means of triplicate results obtained on 
Alinity MS, the estimated bias between Alinity and RMP 
results, and regression parameters obtained by compar-
ing the Alinity means with the expected values are also 
reported. The mean bias was within the optimum quality 
goal for ALT, ALP, CK, γGT, and LDH, while for AST the 
mean bias (+4.4%) fulfilled the desirable APS.
The uncertainties associated with enzyme measure-
ments carried out on the Alinity c system are shown in 
Table 4. U for ALP, AST, and LDH met the corresponding 
desirable APS, whereas ALT, CK, and γGT fulfilled optimal 
U goals, as reported in Table 2.
Results about the transferability between Milan and 
Bydgoszcz Alinity platforms are presented in Table 5. As 
can be seen, the inter-platform bias for all enzymes was 
less than 1/3 of desirable bias goals reported in Table 2. 
According to this criterion, we considered enzyme results 
obtained on the two platforms negligibly biased and, con-
sequently, the Alinity MS standardization to IFCC RMPs, 
shown for the Milan system, was considered perfectly 
transferable to the Bydgoszcz platform.
Discussion
Verification of metrological traceability of IVD medical 
devices in order to demonstrate the standardization of 
results obtained on clinical samples is an essential task 
to guarantee the quality of medical laboratory activities, 
in which laboratory professionals play a key role [17, 18]. 
To make standardization effective, the laboratory results 
should be unbiased (or negligibly biased according to 
the clinically defined APS) and their measurement 
uncertainty, obtained by combining the uncertainty 
accounting for random sources and the uncertainty 
Table 3: Results for the six evaluated enzymes on serum pools obtained by the IFCC reference measurement procedure (RMP) and  
Alinity c measuring system in Milan.
Enzyme   Pool ID   RMP  Mean of three Alinity 
replicates, U/L
  Bias, U/L   Bias, %   Mean bias, %  Regression parameters
Targeta, U/L Ub, %
ALT   L   38.9   5.12  40.0  1.1   2.83   0.44  y = 0.98x + 1.9 U/L, 
R2 = 1.0000  M   78.1   3.43  77.7  −0.4   −0.51
  H   201.3   2.64  199.3  −2.0   −0.99
ALP   L   95.9   3.00  97.0  1.1   1.15   1.78  y = 1.05x – 3.5 U/L, 
R2 = 0.9991  M   310.1   2.57  310.3  0.2   0.06
  H   504.9   2.64  525.7  20.8   4.12
AST   L   30.0   2.53  32.3  2.3   7.67   4.44  y = 1.01x + 2.0 U/L, 
R2 = 1.0000  M   70.4   2.52  72.7  2.3   3.27
  H   172.2   2.60  176.3  4.1   2.38
CK   L   108.6   3.98  110.7  2.1   1.93   0.61  y = 1.02x + 0.1 U/L, 
R2 = 0.9992  M   243.0   3.21  238.3  −4.7   −1.93
  H   461.6   2.55  470.0  8.4   1.82
γGT   L   43.0   3.47  41.3  −1.7   −3.95   −1.83  y = 1.01x − 2.1 U/L, 
R2 = 1.0000  M   84.3   2.68  83.0  −1.3   −1.54
  H   211.3   2.72  211.3  0.0   0.0
LDH   L   220.6   2.70  224.0  3.4   1.54   0.83  y = 0.99x + 5.2 U/L, 
R2 = 1.0000  M   361.3   2.57  363.5  2.2   0.60
  H   442.7  2.66   444.3  1.6   0.36
aMeasurements in triplicate for 3 consecutive days: the target value was calculated as an average of the averages of the daily results. 
bExpanded uncertainty (by a coverage factor of 2). Bias (estimated by comparing the Alinity results with the target values assigned to pools 
by the RMP) and regression data (y = Alinity; x = RMP) are also reported.
Table 4: Measurement uncertainties of enzyme results obtained 
with the Alinity c measuring system.
Enzyme Catalytic activity concentration 
(order of magnitude compared 
to the upper reference limit 
[URL] in adult white malesa)
ubias uRw uresult Ub
ALT 88 U/L (1.5 × URL) 1.9% 1.1% 2.2% 4.4%
ALP 345 U/L (3.0 × URL) 1.3% 1.3% 1.9% 3.8%
AST 204 U/L (6.0 × URL) 2.7% 0.7% 2.8% 5.6%
CK 513 U/L (3.0 × URL) 2.2% 0.6% 2.3% 4.6%
γGT 184 U/L (2.7 × URL) 1.4% 1.4% 2.0% 4.0%
LDH 374 U/L (1.7 × URL) 1.6% 1.4% 2.1% 4.2%
aURL derived from Ref. [6]. bExpanded uncertainty (by a coverage 
factor of 2).
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associated with MS calibration, must fulfill the corre-
sponding APS.
To the best of our knowledge, this is the first study 
aimed to independently verify the level of standardiza-
tion of the procedures for the determination of the cata-
lytic activity of the most clinically relevant enzymes, 
offered by Abbott Diagnostics on the new Alinity c plat-
form. In our study, all evaluated enzyme assays achieved 
at least a desirable level of APS for both bias against the 
 corresponding IFCC RMP and U of clinical samples. This 
confirms the correct implementation by the manufac-
turer of the Alinity enzymes of traceability to higher-order 
references. Furthermore, unbiased measurements were 
consistent between Alinity MSs located in two different 
European laboratories, suggesting the transferability 
of the MS performance. Importantly, these results were 
obtained by applying relatively stringent APS, derived 
from robust biological variation data recently made 
available by EFLM [33]. For evaluating the status of the 
standardization of enzyme measurements by Alinity MS, 
we tested their agreement against RMPs obtained for 
each of the three patient pools. We are aware that using 
pools instead of a panel of native samples may not rep-
resent an optimal approach and theoretically can result 
in non-commutability problems. However, having strictly 
followed the CLSI C37-A recommendations for their prepa-
ration [22, 23], we are confident that our pools may reason-
ably behave as individual clinical samples.
The catalytic activity of an enzyme is a property 
measured by the catalyzed rate of reaction, produced in a 
specific assay system and any variation in components of 
the reaction system may alter the magnitude of the meas-
ured activity [39]. The high stability of the Alinity MS, 
shown by the low values of uRw component (≤1.4% for all 
evaluated enzymes), allows the manufacturer to calibrate 
enzyme assays by constant calibration factors instead 
of using calibrator materials, which may in turn remove 
one of the major sources of variability, i.e. the calibration 
procedure. Often, the largest part of uresult is contributed 
by uRw, which depends on the MS stability over time and 
its variability when employed by individual end-users. 
However, for Alinity enzymes, the major contribution to U 
appears to be ubias. From this point of view, it is extremely 
important to correctly select the right calibration factor, 
when the manufacturer offers alternative choices (ALP 
and γGT). A previous study, performed on the Architect 
platform using a quite similar protocol, revealed that the 
ALP assay calibrated with a calibrator factor derived from 
the p-nitrophenol molar extinction coefficient of an opti-
mized reaction for ALP developed by the manufacturer, 
instead of using the calibrator factor standardized to the 
IFCC RMP, has a clinically significant positive bias [16]. 
Based on the results of our studies, Abbott Diagnostics 
should discontinue to offer in their package inserts the 
so-called ‘theoretical’ calibrator factors, recommending 
to end-users only factors obtained by correlation results 
using clinical samples with RMP-assigned values, which 
allow to achieve an optimal result standardization.
Calculating U for enzyme measurements using a 
single concentration level, as we did in this study, may 
Table 5: Results obtained by measuring enzymes with the Alinity c system in Milan, Italy, and Bydgoszcz, Poland.
Enzyme Pool ID Milan mean of triplicates, U/L Bydgoszcz mean of triplicates, U/L Bias, U/L Bias, % Mean bias, % Goala
ALT 1 39.7 40.3 0.6 1.5 1.23 ±2.6%
2 79.0 80.0 1.0 1.3
3 230.7 232.7 2.0 0.9
ALP 1 113.3 113.3 0 0 −0.30 ±1.8%
2 515.7 512.7 −3.0 −0.6
3 811.3 809.0 −2.3 −0.3
AST 1 38.0 36.7 −1.3 −3.4 −1.83 ±1.9%
2 82.3 81.3 −1.0 −1.2
3 193.7 192.0 −1.7 −0.9
CK 1 95.0 96.0 1.0 1.1 0.97 ±2.9%
2 213.0 215.7 2.7 1.3
3 491.3 493.7 2.4 0.5
γGT 1 37.0 37.0 0 0 −0.53 ±3.5%
2 72.0 70.3 −1.7 −2.4
3 226.0 227.7 1.7 0.8
LDH 1 225.0 226.7 1.7 0.8 0.13 ±1.1%
2 370.7 368.0 −2.7 −0.7
3 878.7 881.3 2.6 0.3
a1/3 of allowable desirable bias reported in Table 2.
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represent a limitation because it would be necessary 
to disseminate its estimates to more than one activity 
across the reportable range [40, 41]. However, it should 
be underlined that we performed this assessment at the 
most important enzyme concentrations near the deci-
sion cut-points employed in the medical application of 
the tests [1].
Traceability to higher-order references is essential to 
assure equivalency of clinical results across MSs and labo-
ratories using them. Our study shows how measurements 
of the most clinically important enzymes on the Alinity c 
MS are correctly standardized to the IFCC RMPs and fulfill 
the APS for U on clinical samples. The transferability of 
the obtained results between two different European 
 laboratories was also demonstrated.
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